Titan Pharmaceuticals Licenses Exclusive Probuphine(R) Commercialization Rights in U.S. and Canada to Braeburn Pharmaceuticals December 17, 2012
Titan Pharmaceuticals Schedules Conference Call to Review Second Quarter 2012 Financial Results August 8, 2012
Titan Completes Preclinical Study of a Continuous, Dopamine Agonist Treatment for Parkinson's Disease July 9, 2012
Titan Pharmaceuticals Schedules Conference Call to Review First Quarter 2012 Financial Results May 9, 2012
Titan Pharmaceuticals Announces Phase 3 Probuphine(R) Data Presentation at the American Society of Addiction Medicine (ASAM) 43rd Medical-Scientific Conference April 20, 2012
